Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017

MRD Timepoints in CLL

August 29th 2017

CLL: Value of MRD Testing

August 29th 2017

Goals of Therapy in CLL

August 29th 2017

Published Data Demonstrate Efficacy of Carfilzomib in Myeloma

August 24th 2017

Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma

Kumar Discusses Latest Developments in Myeloma

August 17th 2017

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

August 9th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

August 4th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Expert Discusses Rapid Advances, Next Steps in Multiple Myeloma

August 4th 2017

Peter Voorhees, MD, discusses treatments for both newly diagnosed and relapsed patients with multiple myeloma.

XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma

August 3rd 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Dr. Friend on the Importance of Work-up for Patients With Multiple Myeloma

August 3rd 2017

Reed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of appropriate work-ups for patients with multiple myeloma.

Usmani Discusses Emergence of CAR T-Cell Therapy in Myeloma

August 1st 2017

Saad Z. Usmani, MD, discusses recent multiple myeloma data, the potential role of CAR T-cell therapy, and what therapeutic advancements the community can expect in the remainder of 2017.

Plethora of Novel Agents Transforming Outcomes in Multiple Myeloma

July 28th 2017

Rachid Baz, MD, discusses the change in risk factors for select treatments, the impact of daratumumab, and current sequencing questions in multiple myeloma.

Myeloma Expert Stresses Significance of Appropriate Diagnostic Work-up

July 28th 2017

Reed Friend, MD, discusses the revised steps in diagnosing patients with multiple myeloma and prognostic factors, as well as existing challenges and hopes for the field’s future.